
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3648170/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serial measurement of pancreatic stone protein for the early detection of sepsis in intensive care unit patients: a prospective multicentric study. Critical Care, 2021, 25, 151.	2.5	25
2	Accuracy of pancreatic stone protein for the diagnosis of infection in hospitalized adults: a systematic review and individual patient level meta-analysis. Critical Care, 2021, 25, 182.	2.5	20
3	Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital. Mycoses, 2021, 64, 1512-1520.	1.8	11
4	Chlorhexidine-dress related contact dermatitis—the precautionary principle is no more relevant!. Critical Care, 2020, 24, 687.	2.5	0
5	Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis. Open Forum Infectious Diseases, 2020, 7, ofaa075.	0.4	26
6	Measurement of pancreatic stone protein in the identification and management of sepsis. Biomarkers in Medicine, 2019, 13, 135-145.	0.6	36
7	Sustained reduction of catheter-associated bloodstream infections with enhancement of catheter bundle by chlorhexidine dressings over 11Âyears. Intensive Care Medicine, 2019, 45, 823-833.	3.9	35
8	Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	9
9	Expert Statements on the Standard of Care in Critically III Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest, 2017, 152, 424-434.	0.4	37
10	Hand Hygiene Improvement and Sustainability: Assessing a Breakthrough Collaborative in Western Switzerland. Infection Control and Hospital Epidemiology, 2017, 38, 1420-1427.	1.0	10
11	Treatment of severe MRSA infections: current practice and further development. Intensive Care Medicine, 2017, 43, 233-236.	3.9	6
12	Procalcitonin-Guided Antibiotics after Surgery for Peritonitis: A Randomized Controlled Study. Gastroenterology Research and Practice, 2017, 2017, 1-6.	0.7	11
13	Management of infections in critically ill returning travellers in the intensive care unit—ll: clinical syndromes and special considerations in immunocompromised patients. International Journal of Infectious Diseases, 2016, 48, 104-112.	1.5	9
14	Antibiotic consumption to detect epidemics of Pseudomonas aeruginosa in a burn centre: A paradigm shift in the epidemiological surveillance of Pseudomonas aeruginosa nosocomial infections. Burns, 2016, 42, 564-570.	1.1	30
15	What is new in selective decontamination of the digestive tract?. Intensive Care Medicine, 2016, 42, 1270-1275.	3.9	10
16	Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis. PLoS ONE, 2016, 11, e0163542.	1.1	15
17	Prognostication of Mortality in Critically 111 Patients With Severe Infections. Chest, 2015, 148, 674-682.	0.4	20
18	The Role of Biomarkers for Starting Antifungals in the Intensive Care Unit. Clinical Pulmonary Medicine, 2015, 22, 286-293.	0.3	1

#	Article	IF	CITATIONS
19	Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU:. European Journal of Hospital Pharmacy, 2015, 22, 123-124.	0.5	0
20	Contextual effect of selective oral decontamination/selective decontamination of the digestive tract on candidemia: just another word of caution!. Intensive Care Medicine, 2015, 41, 2224-2226.	3.9	0
21	Low C-reactive protein values at admission predict mortality in patients with severe community-acquired pneumonia caused by Streptococcus pneumoniae that require intensive care management. Infection, 2015, 43, 193-199.	2.3	10
22	Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Burns, 2015, 41, 956-968.	1.1	47
23	A 3-Step Therapeutic Strategy for Severe Alveolar Proteinosis. Annals of Thoracic Surgery, 2015, 99, 1456-1458.	0.7	4
24	Preventing invasive candida infections. Where could we do better?. Journal of Hospital Infection, 2015, 89, 302-308.	1.4	60
25	A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. Clinical Infectious Diseases, 2015, 61, civ707.	2.9	72
26	Candida colonization index and subsequent infection in critically ill surgical patients: 20Âyears later. Intensive Care Medicine, 2014, 40, 1429-1448.	3.9	107
27	Polymorphisms in Tumor Necrosis Factor-α Increase Susceptibility to Intra-Abdominal Candida Infection in High-Risk Surgical ICU Patients*. Critical Care Medicine, 2014, 42, e304-e308.	0.4	17
28	Intra-abdominal candidiasis: the guidelines—forgotten non-candidemic invasive candidiasis. Intensive Care Medicine, 2013, 39, 2226-2230.	3.9	43
29	β-Glucan Antigenemia Anticipates Diagnosis of Blood Culture–Negative Intraabdominal Candidiasis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1100-1109.	2.5	183
30	Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Critical Care, 2012, 16, R114.	2.5	44
31	Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis?. Critical Care, 2011, 15, 1017.	2.5	13
32	Pancreatic Stone Protein. Chest, 2011, 140, 925-932.	0.4	43
33	Diagnosis of invasive candidiasis in the ICU. Annals of Intensive Care, 2011, 1, 37.	2.2	109
34	Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 1110-1116.	1.3	58
35	Early antifungal intervention strategies in ICU patients. Current Opinion in Critical Care, 2010, 16, 465-469.	1.6	26
36	Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Medicine, 2009, 35, 903-908.	3.9	62

#	Article	IF	CITATIONS
37	On track to limit antifungal overuse!. Intensive Care Medicine, 2009, 35, 582-584.	3.9	8
38	Response to letter to the editor: "Which tobramycin dose is needed in the burn patient?― Burns, 2009, 35, 904-905.	1.1	0
39	On the way towards eradication of catheter-related infections!. Intensive Care Medicine, 2008, 34, 988-990.	3.9	2
40	Management of catheter-related infection. Expert Review of Anti-Infective Therapy, 2008, 6, 31-37.	2.0	17
41	Antifungals in the ICU. Current Opinion in Infectious Diseases, 2008, 21, 610-619.	1.3	36
42	Diagnosis of intravascular catheter infection. Current Opinion in Infectious Diseases, 2007, 20, 353-359.	1.3	20
43	Prevention of intravascular catheter infection. Current Opinion in Infectious Diseases, 2007, 20, 360-369.	1.3	29
44	Single rooms may help to prevent nosocomial bloodstream infection and cross-transmission of methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Medicine, 2007, 33, 836-840.	3.9	110
45	Pro/con debate: antifungal prophylaxis is important to prevent fungal infection in patients with acute necrotizing pancreatitis receiving broad-spectrum antibiotics. Critical Care, 2006, 10, 229.	2.5	17
46	Should Antibiotic Combinations Be Used to Treat Ventilator-Associated Pneumonia?. Seminars in Respiratory and Critical Care Medicine, 2006, 27, 068-081.	0.8	12
47	Postoperative Fungal Infections. Surgical Infections, 2006, 7, s-53-s-56.	0.7	5
48	Treatment options of invasive fungal infections in adults. Swiss Medical Weekly, 2006, 136, 447-63.	0.8	62
49	Long-Term Reduction of Vascular Access–Associated Bloodstream Infection. Annals of Internal Medicine, 2005, 142, 875.	2.0	38
50	Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?. Intensive Care Medicine, 2005, 31, 1466-1468.	3.9	16
51	Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists. Intensive Care Medicine, 2005, 31, 1514-1521.	3.9	30
52	Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000. Clinical Infectious Diseases, 2004, 38, 311-320.	2.9	401
53	Catheter-related infections. Microbes and Infection, 2004, 6, 1033-1042.	1.0	78
54	Impact of Ventilator-Associated Pneumonia on Resource Utilization and Patient Outcome. Infection Control and Hospital Epidemiology, 2004, 25, 1090-1096.	1.0	76

#	Article	IF	CITATIONS
55	Nosocomial Bloodstream Infection and Clinical Sepsis. Emerging Infectious Diseases, 2004, 10, 76-81.	2.0	86
56	Ventilator-associated pneumonia: caveats for benchmarking. Intensive Care Medicine, 2003, 29, 2086-2089.	3.9	94
57	Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infectious Diseases, The, 2003, 3, 685-702.	4.6	766
58	Management of candidiasis Management of Candida species infections in critically ill patients. Lancet Infectious Diseases, The, 2003, 3, 772-785.	4.6	234
59	Acute Respiratory Distress Syndrome after Bacteremic Sepsis Does Not Increase Mortality. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1210-1214.	2.5	20
60	Prevention of Ventilator-associated Pneumonia by Oral Decontamination. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 338-339.	2.5	16
61	Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet, The, 2000, 355, 1864-1868.	6.3	424
62	Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Critical Care Medicine, 1999, 27, 1066-1072.	0.4	433
63	Pacemaker and Defibrillator Infections. , 0, , 247-264.		24